Gareth Maher‐Edwards

490 total citations
16 papers, 390 citations indexed

About

Gareth Maher‐Edwards is a scholar working on Pharmacology, Psychiatry and Mental health and Physiology. According to data from OpenAlex, Gareth Maher‐Edwards has authored 16 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 8 papers in Psychiatry and Mental health and 3 papers in Physiology. Recurrent topics in Gareth Maher‐Edwards's work include Cholinesterase and Neurodegenerative Diseases (9 papers), Dementia and Cognitive Impairment Research (8 papers) and Alzheimer's disease research and treatments (3 papers). Gareth Maher‐Edwards is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (9 papers), Dementia and Cognitive Impairment Research (8 papers) and Alzheimer's disease research and treatments (3 papers). Gareth Maher‐Edwards collaborates with scholars based in United Kingdom, United States and Germany. Gareth Maher‐Edwards's co-authors include Michael Gold, Pauline Williams, Marina Zvartau‐Hind, Jackie Hunter, Andrea Hunter, Ruth Dixon, Carly Barnett, Arseniy Lavrov, Andrew Lockhart and Joakim Nyberg and has published in prestigious journals such as Nature Medicine, Journal of Alzheimer s Disease and Alzheimer s & Dementia.

In The Last Decade

Gareth Maher‐Edwards

15 papers receiving 375 citations

Peers

Gareth Maher‐Edwards
Clara Torrellas Spain
Juan C. Carril Spain
Lennart Meurling Sweden
D. Hadler Germany
Priya Singhal United States
Yilin Xia China
Irena Loryan Sweden
Huaqiu Chen China
Stacey L. Becker United States
Xinchao Hu China
Clara Torrellas Spain
Gareth Maher‐Edwards
Citations per year, relative to Gareth Maher‐Edwards Gareth Maher‐Edwards (= 1×) peers Clara Torrellas

Countries citing papers authored by Gareth Maher‐Edwards

Since Specialization
Citations

This map shows the geographic impact of Gareth Maher‐Edwards's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gareth Maher‐Edwards with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gareth Maher‐Edwards more than expected).

Fields of papers citing papers by Gareth Maher‐Edwards

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gareth Maher‐Edwards. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gareth Maher‐Edwards. The network helps show where Gareth Maher‐Edwards may publish in the future.

Co-authorship network of co-authors of Gareth Maher‐Edwards

This figure shows the co-authorship network connecting the top 25 collaborators of Gareth Maher‐Edwards. A scholar is included among the top collaborators of Gareth Maher‐Edwards based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gareth Maher‐Edwards. Gareth Maher‐Edwards is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Diacon, Andreas H., Clifton E. Barry, Ray Y. Chen, et al.. (2024). A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature Medicine. 30(3). 896–904. 20 indexed citations
2.
3.
Farnoud, Ali, Joakim Nyberg, Sebastian G. Wicha, et al.. (2022). Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin. Pharmaceutics. 14(8). 1530–1530. 54 indexed citations
4.
Maher‐Edwards, Gareth, et al.. (2015). A 24‐week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 1(2). 131–140. 35 indexed citations
5.
Maher‐Edwards, Gareth, Carolyn Watson, John A. Ascher, et al.. (2015). Two randomized controlled trials of SB742457 in mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 1(1). 23–36. 42 indexed citations
6.
Maher‐Edwards, Gareth, et al.. (2014). A 24‐WEEK STUDY TO EVALUATE THE EFFECT OF RILAPLADIB ON COGNITION AND CSF MARKERS OF ALZHEIMER'S DISEASE. Alzheimer s & Dementia. 10(4S_Part_5). 1 indexed citations
7.
Maher‐Edwards, Gareth, John A. Ascher, Carolyn J. Watson, et al.. (2011). O4‐06‐06: 48‐week efficacy and tolerability of treatment with SB‐742457, a novel 5HT6 receptor antagonist, when added on to donepezil in subjects with mild‐to‐moderate Alzheimer's disease (AD). Alzheimer s & Dementia. 7(4S_Part_24). 5 indexed citations
8.
Maher‐Edwards, Gareth, Marina Zvartau‐Hind, John B. Davies, et al.. (2011). P4‐213: Effects of 6‐month monotherapy treatment with the 5HT6 receptor antagonist SB 742457 or donepezil in subjects with mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia. 7(4S_Part_22). 1 indexed citations
9.
10.
Maher‐Edwards, Gareth, et al.. (2010). SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. International Journal of Geriatric Psychiatry. 26(5). 536–544. 92 indexed citations
11.
Maher‐Edwards, Gareth, et al.. (2010). Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimers Disease. Current Alzheimer Research. 7(5). 374–385. 99 indexed citations
12.
Maher‐Edwards, Gareth, et al.. (2010). Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease. Current Alzheimer Research. 999(999). 1–12. 8 indexed citations
13.
Randolph, Christopher & Gareth Maher‐Edwards. (2010). P3‐121: Use of the RBANS as a cognitive endpoint in Alzheimer clinical trials. Alzheimer s & Dementia. 6(4S_Part_16). 1 indexed citations
14.
Irizarry, Michael C., David J. Webb, Chanchal Bains, et al.. (2008). Predictors of Placebo Group Decline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in 24 Week Clinical Trials of Alzheimer's Disease. Journal of Alzheimer s Disease. 14(3). 301–311. 25 indexed citations
15.
16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Clara Torrellas Breakdown of academic impact, for papers by Juan C. Carril Breakdown of academic impact, for papers by Lennart Meurling Breakdown of academic impact, for papers by D. Hadler Breakdown of academic impact, for papers by Priya Singhal Breakdown of academic impact, for papers by Yilin Xia Breakdown of academic impact, for papers by Irena Loryan Breakdown of academic impact, for papers by Huaqiu Chen Breakdown of academic impact, for papers by Stacey L. Becker Breakdown of academic impact, for papers by Xinchao Hu
Rankless by CCL
2026